Skip to main content
Have a personal or library account? Click to login
Non-thermal ablation and drug delivery by electroporation: expanding current indications beyond cancer and cardiac treatment Cover

Non-thermal ablation and drug delivery by electroporation: expanding current indications beyond cancer and cardiac treatment

Open Access
|Aug 2026

References

  1. Kotnik T, Rems L, Tarek M, Miklavčič D. Membrane electroporation and electropermeabilization: mechanisms and models. Annu Rev Biophys 2019; 48: 63-91. doi: 10.1146/annurev-biophys-052118-115451
  2. Serša G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M. Electrochemotherapy in treatment of tumours. Eur J. Surg Oncol 2008; 34: 232-40. doi: 10.1016/j.ejso.2007.05.016
  3. Orlowski S, Belehradek J, Paoletti C, Mir LM. Transient electropermeabilization of cells in culture: increase of the cytotoxicity of anticancer drugs. Biochem Pharmacol 1988; 37: 4727-33. doi: 10.1016/0006-2952(88)90344-9
  4. Heller R, Heller LC. Chapter Eight - Gene Electrotransfer Clinical Trials. In: Huang L, Liu D, Wagner E, editors Advances in Genetics. Academic Press; 2015. p. 235-62. doi: 10.1016/bs.adgen.2014.10.006
  5. Sachdev S, Potočnik T, Rems L, Miklavčič D. Revisiting the role of pulsed electric fields in overcoming the barriers to in vivo gene electrotransfer. Bioelectrochemistry 2022; 144: 107994. doi: 10.1016/j.bioelech-em.2021.107994
  6. Davalos RV, Mir ILM, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng 2005; 33: 223-31. doi: 10.1007/s10439-005-8981-8
  7. Geboers B, Scheffer HJ, Graybill PM, Ruarus AH, Nieuwenhuizen S, Puijk RS, et al. High-voltage electrical pulses in oncology: irreversible electroporation, electrochemotherapy, gene electrotransfer, electrofusion, and electroimmunotherapy. Radiology 2020; 295: 254-72. doi: 10.1148/radiol.2020192190
  8. Ekanem E, Neuzil P, Reichlin T, Kautzner J, Van Der Voort P, Jais P, et al. Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study. Nat Med 2024; 30: 2020-9. doi: 10.1038/s41591-024-03114-3
  9. Miklavčič D, Verma A, Krahn PRP, Štublar J, Kos B, Escartin T, et al. Biophysics and electrophysiology of pulsed field ablation in normal and infarcted porcine cardiac ventricular tissue. Sci Rep 2024; 14: 32063. doi: 10.1038/s41598-024-83683-y
  10. Cannon R, Ellis S, Hayes D, Narayanan G, Martin RCG. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. J Surg Oncol 2013; 107: 544-9. doi: 10.1002/jso.23280
  11. Sutter O, Calvo J, N’Kontchou G, Nault J-C, Ourabia R, Nahon P, et al. Safety and efficacy of irreversible electroporation for the treatment of hepatocellular carcinoma not amenable to thermal ablation techniques: a retrospective single-center case series. Radiology 2017; 284: 877-86. doi: 10.1148/radiol.2017161413
  12. Jarm T, Cemazar M, Miklavcic D, Sersa G. Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. Expert Rev Anticancer Ther 2010; 10: 729-46. doi: 10.1586/era.10.43
  13. Brinton M, Mandel Y, Schachar I, Palanker D. Mechanisms of electrical vasoconstriction. J Neuroeng Rehabil 2018; 15: 43. doi: 10.1186/s12984-018-0390-y
  14. Calvet CY, Mir LM. The promising alliance of anti-cancer electrochemotherapy with immunotherapy. Cancer Metastasis Rev 2016; 35: 165-77. doi: 10.1007/s10555-016-9615-3
  15. Scheffer HJ, Stam AGM, Geboers B, Vroomen LGPH, Ruarus A, de Bruijn B, et al. Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation. Oncoimmunology 2019; 8: 1652532. doi: 10.1080/2162402X.2019.1652532
  16. Zhao J, Wen X, Tian L, Li T, Xu C, Wen X, et al. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. Nat Commun 2019; 10: 899. doi: 10.1038/s41467-019-08782-1
  17. Kesar U, Markelc B, Jesenko T, Valentinuzzi KU, Cemazar M, Strojan P, et al. Effects of electrochemotherapy on immunologically important modifications in tumor cells. Vaccines 2023; 11: doi: 10.3390/vaccines11050925
  18. Mir LM, Belehradek M, Domenge C, Orlowski S, Poddevin B, Belehradek J, et al. [Electrochemotherapy, a new antitumor treatment: first clinical trial]. [French]. C R AcadSci III 1991; 313: 613-8. PMID: 1723647
  19. Mir LM, Gehl J, Sersa G, Collins CG, Garbay J-R, Billard V, et al. Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. Eur J Cancer Suppl 2006; 4: 14-25. doi: 10.1016/j.ejcsup.2006.08.003
  20. Gehl J, Sersa G, Matthiessen LW, Muir T, Soden D, Occhini A, et al. Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases. Acta Oncol 2018; 57: 874-82. doi: 10.1080/0284186X.2018.1454602
  21. Campana LG, Edhemovic I, Soden D, Perrone AM, Scarpa M, Campanacci L, et al. Electrochemotherapy - emerging applications technical advances, new indications, combined approaches, and multi-institutional collaboration. Eur J Surg Oncol 2019; 45: 92-102. doi: 10.1016/j.ejso.2018.11.023
  22. Clover AJP, de Terlizzi F, Bertino G, Curatolo P, Odili J, Campana LG, et al. Electrochemotherapy in the treatment of cutaneous malignancy: outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochemotherapy database for 2482 lesions in 987 patients (2008–2019). Eur J Cancer 2020; 138: 30-40. doi: 10.1016/j.ejca.2020.06.020
  23. Lyons P, Polini D, Russell-Ryan K, Clover AJP. High-frequency electroporation and chemotherapy for the treatment of cutaneous malignancies: evaluation of early clinical response. Cancers (Basel) 2023; 15: 3212. doi: 10.3390/cancers15123212
  24. Linnert M, Iversen HK, Gehl J. Multiple brain metastases - current management and perspectives for treatment with electrochemotherapy. Radiol Oncol 2012; 46: 271-8. doi: 10.2478/v10019-012-0042-y
  25. Djokic M, Cemazar M, Popovic P, Kos B, Dezman R, Bosnjak M, et al. Electrochemotherapy as treatment option for hepatocellular carcinoma, a prospective pilot study. Eur J Surg Oncol 2018; 44: 651-7. doi: 10.1016/j.ejso.2018.01.090
  26. Izzo F, Granata V, Fusco R, D’Alessio V, Petrillo A, Lastoria S, et al. Clinical Phase I/II study: local disease control and survival in locally advanced pancreatic cancer treated with electrochemotherapy. J Clin Med 2021; 10: 1305. doi: 10.3390/jcm10061305
  27. Luerken L, Doppler M, Brunner SM, Schlitt HJ, Uller W. Stereotactic percutaneous electrochemotherapy as primary approach for unresectable large HCC at the hepatic hilum. Cardiovasc Intervent Radiol 2021; 44: 1462-6. doi: 10.1007/s00270-021-02841-1
  28. Campanacci L, Cevolani L, De Terlizzi F, Saenz L, Alì N, Bianchi G, et al. Electrochemotherapy is effective in the treatment of bone metastases. Curr Oncol 2022; 29: 1672-82. doi: 10.3390/curroncol29030139
  29. Granata V, Fusco R, D’Alessio V, Simonetti I, Grassi F, Silvestro L, et al. Percutanous electrochemotherapy (ECT) in primary and secondary liver malignancies: a systematic review. Diagnostics 2023; 13: 209. doi: 10.3390/diagnostics13020209
  30. Stevanovic M, Heringer M, Hjouj M, Zanasi A, Terlizzi F de, Stehling MK. Prostate cancer treatment with electrochemotherapy (ECT): safety, efficacy and clinical experience in 144 patients. Radiol Oncol 2025; 59: 597-606. doi: 10.2478/raon-2025-0061
  31. Vivod G, Cilensek I, Kovacevic N, Sersa G, Cemazar M, Merlo S. Quality of life of women with recurrent vulvar cancer treated with electrochemotherapy. Radiol Oncol 2025; 59: 267-76. doi: 10.2478/raon-2025-0019
  32. Deschamps F, Tselikas L, Yevich S, Bonnet B, Roux C, Kobe A, et al. Electrochemotherapy in radiotherapy-resistant epidural spinal cord compression in metastatic cancer patients. Eur J Cancer 2023; 186: 62-8. doi: 10.1016/j.ejca.2023.03.012
  33. Deschamps F, Tselikas L, Cazzato RL, Facchini G, Granata V, Bonnet B, et al. Electrochemotherapy in metastatic epidural spinal cord compression: a review and technical update. Br J Radiol 2025; 98: 828-39. doi: 10.1093/bjr/tqae219
  34. Falk Hansen H, Bourke M, Stigaard T, Clover J, Buckley M, O’Riordain M, et al. Electrochemotherapy for colorectal cancer using endoscopic electroporation: a phase 1 clinical study. Endosc Int Open 2020; 8: E124-32. doi: 10.1055/a-1027-6735
  35. Broholm M, Vogelsang R, Bulut M, Gögenur M, Stigaard T, Orhan A, et al. Neoadjuvant calcium electroporation for potentially curable colorectal cancer. Surg Endosc 2024; 38: 697-705. doi: 10.1007/s00464-023-10557-1
  36. Adeyeye A, Haji A. Establishing a salvage endoscopic electroporation (SEE) service for colorectal cancer: the King’s protocol for clinical implementation. J Clin Med 2025; 14: 8436. doi: 10.3390/jcm14238436
  37. Adeyeye A, Olabintan O, Ayubi H, Gao H, Saini A, Emmanuel A, et al. Palliative luminal treatment of colorectal cancer using endoscopic calcium-electroporation: first case series from United Kingdom. J Clin Med 2025; 14: 4138. doi: 10.3390/jcm14124138
  38. Bonura GF, Gualandi N, Soriani P, Cortegoso Valdivia P, Gabbani T, Zadro V, et al. Pioneering endoscopic calcium-electroporation in gastric cancer: a case series of an emerging therapeutic approach. Diseases 2025; 13: 340. doi: 10.3390/diseases13100340
  39. Pellegrino R, Nacca V, Paragliola F, Martinelli E, Federico A, Gravina AG. Endoscopic calcium electroporation for unfit-for-surgery bleeding colorectal cancer: the dawn of a new treatment? Minerva Med 2026; 117: 55-7. doi: 10.23736/S0026-4806.24.09270-X
  40. Egeland C, Baeksgaard L, Johannesen HH, Löfgren J, Plaschke CC, Svendsen LB, et al. Endoscopic electrochemotherapy for esophageal cancer: a phase I clinical study. Endosc Int Open 2018; 6: E727-34. doi: 10.1055/a-0590-4053
  41. Egeland C, Baeksgaard L, Gehl J, Gögenur I, Achiam MP. Palliative treatment of esophageal cancer using calcium electroporation. Cancers (Basel) 2022; 14: 5283. doi: 10.3390/cancers14215283
  42. Cvetkoska A, Pírc E, Reberšek M, Magjarević R, Míklavčič D. Towards standardization of electroporation devices and protocols. IEEE Instrum Meas Mag 2020; 23: 74-81. doi: 10.1109/MIM.2020.9062692
  43. Al-Sakere B, André F, Bernat C, Connault E, Opolon P, Davalos RV, et al. Tumor ablation with irreversible electroporation. PLoS One 2007; 2: e1135. doi: 10.1371/journal.pone.0001135
  44. Narayanan G, Gentile NT, Eyshi J, Schiro BJ, Gandhi RT, Peña CS, et al. Irreversible electroporation in treating colorectal liver metastases in proximity to critical structures. J Vasc Interv Radiol 2024; 35: 1806-13. doi: 10.1016/j.jvir.2024.08.021
  45. van den Bos W, Scheltema MJ, Siriwardana AR, Kalsbeek AMF, Thompson JE, Ting F, et al. Focal irreversible electroporation as primary treatment for localized prostate cancer. BJU Int. 2018; 121: 716-24. doi: 10.1111/bju.13983
  46. Niessen C, Thumann S, Beyer L, Pregler B, Kramer J, Lang S, et al. Percutaneous irreversible electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors. Sci Rep 2017; 7: 43687. doi: 10.1038/srep43687
  47. Martin RCG, Durham AN, Besselink MG, Iannitti D, Weiss MJ, Wolfgang CL, et al. Irreversible electroporation in locally advanced pancreatic cancer: a call for standardization of energy delivery. J Surg Oncol 2016; 114: 865-71. doi: 10.1002/jso.24404
  48. Narayanan G, Hosein PJ, Beulaygue IC, Froud T, Scheffer HJ, Venkat SR, et al. Percutaneous image-guided irreversible electroporation for the treatment of unresectable, locally advanced pancreatic adenocarcinoma. J Vasc Interv Radiol 2017; 28: 342-8. doi: 10.1016/j.jvir.2016.10.023
  49. Ruarus AH, Vroomen LGPH, Geboers B, van Veldhuisen E, Puijk RS, Nieuwenhuizen S, et al. Percutaneous irreversible electroporation in locally advanced and recurrent pancreatic cancer (PANFIRE-2): a multicenter, prospective, single-arm, phase II study. Radiology 2019; 294: 212-20. doi: 10.1148/radiol.2019191109
  50. Reddy VY, Koruth J, Jais P, Petru J, Timko F, Skalsky I, et al. Ablation of atrial fibrillation with pulsed electric fields: an ultra-rapid, tissue-selective modality for cardiac ablation. JACC Clin Electrophysiol 2018; 4: 987-95. doi: 10.1016/j.jacep.2018.04.005
  51. Verma A, Haines DE, Boersma LV, Sood N, Natale A, Marchlinski FE, et al. Pulsed field ablation for the treatment of atrial fibrillation: PULSED AF pivotal trial. Circulation 2023; 147: 1422-32. doi: 10.1161/CIRCULATIONAHA.123.063988
  52. Della Rocca DG, Cespón-Fernández M, Keelani A, Raffa S, Pannone L, Almorad A, et al. Focal pulsed field ablation for premature ventricular contractions: a multicenter experience. Circ Arrhythm Electrophysiol 2024; 17: e012826. doi: 10.1161/CIRCEP.124.012826
  53. Reddy VY, Gerstenfeld EP, Natale A, Whang W, Cuoco FA, Patel C, et al. Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation. N Engl J Med 2023; 389: 1660-71. doi: 10.1056/NEJMoa2307291
  54. Reichlin T, Kueffer T, Badertscher P, Jüni P, Knecht S, Thalmann G, et al. Pulsed field or cryoballoon ablation for paroxysmal atrial fibrillation. N Engl J Med 2025; 392: 1497-507. doi: 10.1056/NEJMoa2502280
  55. Jais P, Neuzil P, Scherr D, Frison E, Knecht S, Boveda S, et al. Pulsed field vs radiofrequency ablation for paroxysmal atrial fibrillation: the BEAT PAROXAF trial. Eur Heart J 2026; 47: 1527-37. doi: 10.1093/eurheartj/ehaf1115
  56. Reddy VY, Gerstenfeld EP, Schmidt B, Nair D, Natale A, Saliba W, et al. Pulsed field ablation for persistent atrial fibrillation: 1-Year Results of ADVANTAGE AF. J Am Coll Cardiol 2025; 85: 1664-78. doi: 10.1016/j.jacc.2025.03.515
  57. Kühne M, Badertscher P, Andrade JG, Anic A, Chun J, Dello Russo A, et al. Pulsed field ablation for the interventional treatment of atrial fibrillation. A scientific statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS) and the Canadian Heart Rhythm Society (CHRS). Europace 2026; 28: euag080. doi: 10.1093/europace/euag080
  58. Verma A, Hocini M, Andrade J, Gerstenfeld E, Kapa S, Lakkireddy D, et al. 2026 HRS/EHRA scientific statement on pulsed field ablation for cardiac arrhythmias. Heart Rhythm 2026; 13: S1547-5271(26)00124-4. doi: 10.1016/j.hrthm.2026.02.006
  59. Dasa O, Younis A, Higuchi K, Sroubek J, Lee JZ, Chung R, et al. Early U.S. experience with catheter ablation of ventricular arrhythmias with a dual-energy lattice-tip catheter: insights from the CLEAR-VT registry. JACC Clin Electrophysiol 2026; 6: S2405-500X(26)00238-0. doi: 10.1016/j.jacep.2026.03.002
  60. Busch CBE, Meiring S, van Baar ACG, Holleman F, Nieuwdorp M, Bergman JJGHM. Recellularization via electroporation therapy of the duodenum combined with glucagon-like peptide-1 receptor agonist to replace insulin therapy in patients with type 2 diabetes: 12-month results of a first-inhuman study. Gastrointest Endosc 2024; 100: 896-904. doi: 10.1016/j.gie.2024.04.2904
  61. O’Neal DN, Sartoretto A, Holt BA, Abu Dayyeh BK, Vaughan R, Cameron G, et al. Safety, feasibility, and dose-dependent metabolic effects of endoscopic duodenal pulsed electric field therapy in adults with type 2 diabetes: results from two multicentre proof-of-concept studies. Diabetes Obes Metab 2026; 28: 3367-76. doi: 10.1111/dom.70533
  62. Abu Dayyeh BK, Asirvatham SJ. Nonthermal pulsed electric field recellularization in the duodenum for type 2 diabetes mellitus. VideoGIE 2024; 9: 530-2. doi: 10.1016/j.vgie.2024.08.013
  63. Valipour A, Fernandez-Bussy S, Ing AJ, Steinfort DP, Snell GI, Williamson JP, et al. Bronchial rheoplasty for treatment of chronic bronchitis. Twelvemonth results from a multicenter clinical trial. Am J Respir Crit Care Med 2020; 202: 681-9. doi: 10.1164/rccm.201908-1546OC
  64. Sciurba FC, Dransfield MT, Kim V, Marchetti N, Comellas A, Hogarth DK, et al. Bronchial rheoplasty for chronic bronchitis: 2-year results from a US feasibility study with RheOx. BMJ Open Respir Res 2023; 10: e001710. doi: 10.1136/bmjresp-2023-001710
  65. Brock J, Herth F, Darwiche K, Hübner R-H, Skowasch D, Schwick B, et al. Bronchial rheoplasty for chronic bronchitis: real-world evidence of safety and performance. ERJ Open Res 2025; 11: doi: 10.1183/23120541.00480-2025
  66. Meininger GR, Neal RE, Hunter DW, Krimsky WS. Absence of arrhythmogenicity with biphasic pulsed electric fields delivered to porcine airways. Ann Biomed Eng 2024; 52: 1-11. doi: 10.1007/s10439-023-03190-5
  67. Muir T, Bertino G, Groselj A, Ratnam L, Kis E, Odili J, et al. Bleomycin electrosclerotherapy (BEST) for the treatment of vascular malformations. An International Network for Sharing Practices on Electrochemotherapy (InspECT) study group report. Radiol Oncol 2023; 57: 141-9. doi: 10.2478/raon-2023-0029
  68. Haehl J, Haeberle B, Muensterer O, Hartel A, Fröba-Pohl A, Dussa CU, et al. Bleomycin electrosclerotherapy (BEST) of slow-flow vascular malformations (SFVMs) in children. J Pediatr Surg 2025; 60: 162631. doi: 10.1016/j.jpedsurg.2025.162631
  69. Muir T, Wohlgemuth WA, Cemazar M, Bertino G, Groselj A, Ratnam LA, et al. Current Operating Procedure (COP) for Bleomycin ElectroScleroTherapy (BEST) of low-flow vascular malformations. Radiol Oncol 2024; 58: 469-79. doi: 10.2478/raon-2024-0061
  70. Sersa G, Krzic M, Sentjurc M, Ivanusa T, Beravs K, Kotnik V, et al. Reduced blood flow and oxygenation in SA-1 tumours after electrochemotherapy with cisplatin. Br J Cancer 2002; 87: 1047-54. doi: 10.1038/sj.bjc.6600606
  71. Lisec B, Cemazar M, Muir T, Omerzel M, Jesenko T, Markelc B, et al. Bleomycin ElectroScleroTherapy (BEST): mechanistic parallels to electrochemotherapy, experimental models, and unresolved questions. Radiol Oncol 2026; 60: 1-14. doi: 10.2478/raon-2026-0017
  72. Wohlgemuth WA, Müller-Wille R, Meyer L, Wildgruber M, Guntau M, Heydt S von der, et al. Bleomycin electrosclerotherapy in therapy-resistant venous malformations of the body. J Vasc Surg Venous Lymphat Disord 2021; 9: 731-9. doi: 10.1016/j.jvsv.2020.09.009
  73. Schmidt VF, Cangir Ö, Meyer L, Goldann C, Hengst S, Brill R, et al. Outcome of bleomycin electrosclerotherapy of slow-flow malformations in adults and children. Eur Radiol 2024; 34: 6425-34. doi: 10.1007/s00330-024-10723-6
  74. Loeser JH, Guntau M, Bidakov O, von der Heydt S, Gussew A, Schob S, et al. Therapy of lymphatic malformations or isolated lymphatic components in combined slow-flow malformations with bleomycin electrosclerotherapy (BEST). Rofo 2025; 198: 624-34. doi: 10.1055/a-2648-6555
  75. Spiezia S, Offi C, Misso C, Antonelli G, Nuccitelli R, Tufano RP, et al. First-in-human clinical feasibility study of ablation of benign thyroid nodules using nanosecond pulsed field ablation. Thyroid 2025; 35: 1024-9. doi: 10.1177/10507256251372166
  76. Lambricht L, Lopes A, Kos S, Sersa G, Préat V, Vandermeulen G. Clinical potential of electroporation for gene therapy and DNA vaccine delivery. Expert Opin Drug Deliv 2016; 13: 295-310. doi: 10.1517/17425247.2016.1121990
  77. Rosazza C, Meglic SH, Zumbusch A, Rols M-P, Miklavcic D. Gene Electrotransfer: a Mechanistic Perspective. Curr Gene Ther 2016; 16: 98-129. doi: 10.2174/1566523216666160331130040
  78. Heller LC, Singh JS, Synowiec JC, Cherukuri PK, Phan N, Shi G, et al. Effective gene immunotherapy for melanoma utilizing an advanced in vivo electrotransfer system. Mol Ther Oncol 2025; 33: 201035. doi: 10.1016/j.omton.2025.201035
  79. Strojan P, Jesenko T, Omerzel M, Jamsek C, Groselj A, Tratar UL, et al. Phase I trial of phIL12 plasmid intratumoral gene electrotransfer in patients with basal cell carcinoma in head and neck region. Eur J Surg Oncol 2025; 51: 109574. doi: 10.1016/j.ejso.2025.109574
  80. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26: 5896-903. doi: 10.1200/JCO.2007.15.6794
  81. Spanggaard I, Snoj M, Cavalcanti A, Bouquet C, Sersa G, Robert C, et al. Gene electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in disseminated melanoma: safety and efficacy results of a phase I first-in-man study. Hum Gene Ther Clin Dev 2013; 24: 99-107. doi: 10.1089/humc.2012.240
  82. Bulysheva A, Heller L, Francis M, Varghese F, Boye C, Heller R. Monopolar gene electrotransfer enhances plasmid DNA delivery to skin. Bioelectrochemistry 2021; 140: 107814. doi: 10.1016/j.bioelechem.2021.107814
  83. Edelblute C, Mangiamele C, Heller R. Moderate heat-assisted gene electrotransfer as a potential delivery approach for protein replacement therapy through the skin. Pharmaceutics 2021; 13: 1908. doi: 10.3390/pharmaceutics13111908
  84. Simon J, Jouanmiqueou B, Rols M-P, Flahaut E, Golzio M. Transdermal delivery of macromolecules using two-in-one nanocomposite device for skin electroporation. Pharmaceutics 2021; 13: 1805. doi: 10.3390/pharmaceutics13111805
  85. Bulysheva AA, Burcus N, Lundberg CG, Francis MP, Heller R. VEGF-B electrotransfer mediated gene therapy induces cardiomyogenesis in a rat model of cardiac ischemia. Bioelectrochemistry 2018; 124: 105-11. doi: 10.1016/j.bioelechem.2018.07.007
  86. Boye C, Arpag S, Burcus N, Lundberg C, DeClemente S, Heller R, et al. Cardioporation enhances myocardial gene expression in rat heart. Bioelectrochemistry 2021; 142: 107892. doi: 10.1016/j.bioelechem.2021.107892
  87. Aboul-Ella H, Gohar A, Ali AA, Ismail LM, Mahmoud AEE-R, Elkhatib WF, et al. Monoclonal antibodies: from magic bullet to precision weapon. Mol Biomed 2024; 5: 47. doi: 10.1186/s43556-024-00210-1
  88. Hollevoet K, De Smidt E, Geukens N, Declerck P. Prolonged in vivo expression and anti-tumor response of DNA-based anti-HER2 antibodies. Oncotarget 2018; 9: 13623-36. doi: 10.18632/oncotarget.24426
  89. Esquivel RN, Patel A, Kudchodkar SB, Park DH, Stettler K, Beltramello M, et al. In vivo delivery of a DNA-encoded monoclonal antibody protects non-human primates against Zika virus. Mol Ther 2019; 27: 974-85. doi: 10.1016/j.ymthe.2019.03.005
  90. Cuypers M-L, Geukens N, Hollevoet K, Declerck P, Dewilde M. Exploring the fate of antibody-encoding pDNA after intramuscular electroporation in mice. Pharmaceutics 2023; 15: 1160. doi: 10.3390/pharmaceutics15041160
  91. Tebas P, Patel A, Agnes JT, Parzych EM, Baer A, Caturla M, et al. Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial. Nat Med 2025; 31: 4150-9. doi: 10.1038/s41591-025-03969-0
  92. Miklavčič D. Network for development of electroporation-based technologies and treatments: COST TD1104. J Membr Biol 2012; 245: 591-8. doi: 10.1007/s00232-012-9493-8
  93. Gehl J, Pereira PL, Cantwell CP, Deschamps F, Kocijancic A, Schmidt N, et al. Tumor ablation: emerging uses, challenges, and strategic implementation. A green paper by the Network of Expertise in Cancer (JANE-2), High Tech Medical Resources, network on Physical Methods of Tumor Ablation. Radiol Oncol 2026; 60: 153-65. doi: 10.2478/raon-2026-0030
  94. Casali PG, Antoine-Poirel H, Berrocoso S, Blay J-Y, Dubois T, Ferrari A, et al. Health networking on cancer in the European Union: a ‘green paper’ by the EU Joint Action on Networks of Expertise (JANE). ESMO Open 2025; 10: 104126. doi: 10.1016/j.esmoop.2024.104126
  95. Mathy RM, Tinoush P, da Florencia RD, Braun A, Ghamarnejad O, Radeleff B, et al. Impact of needle positioning on ablation success of irreversible electroporation: a unicentric retrospective analysis. Sci Rep 2020; 10: 21902. doi: 10.1038/s41598-020-78660-0
  96. Cindrič H, Kos B, Miklavčič D. Electrodes and electric field distribution in clinical practice. In: Impellizeri JA, editor. Electroporation in veterinary oncology practice: electrochemotherapy and gene electrotransfer for immunotherapy. Cham: Springer International Publishing; 2021. p. 21-59. doi: 10.1007/978-3-030-80668-2_2
  97. Andrade DLLS, Guedert R, Pintarelli GB, Rangel MMM, Oliveira KD, Quadros PG, et al. Electrochemotherapy treatment safety under parallel needle deflection. Sci Rep 2022; 12: 2766. doi: 10.1038/s41598-022-06747-x
  98. Grošelj A, Kos B, Čemažar M, Urbančič J, Kragelj G, Bošnjak M, et al. Coupling treatment planning with navigation system: a new technological approach in treatment of head and neck tumors by electrochemotherapy. Biomed Eng Online 2015; 14 (Suppl 3): S2. doi: 10.1186/1475-925X-14-S3-S2
  99. Kos B, Voigt P, Miklavcic D, Moche M. Careful treatment planning enables safe ablation of liver tumors adjacent to major blood vessels by percutaneous irreversible electroporation (IRE). Radiol Oncol 2015; 49: 234-41. doi: 10.1515/raon-2015-0031
  100. Garcia PA, Kos B, Rossmeisl JH, Pavliha D, Miklavčič D, Davalos RV. Predictive therapeutic planning for irreversible electroporation treatment of spontaneous malignant glioma. Med Phys 2017; 44: 4968-80. doi: 10.1002/mp.12401
  101. Cindrič H, Mariappan P, Beyer L, Wiggermann P, Moche M, Miklavčič D, et al. Retrospective study for validation and improvement of numerical treatment planning of irreversible electroporation ablation for treatment of liver tumors. IEEE Trans Biomed Eng 2021; 68: 3513-24. doi: 10.1109/TBME.2021.3075772
  102. Padia SA, Johnson GE, Yeung RS, Park JO, Hippe DS, Kogut MJ. Irreversible electroporation in patients with hepatocellular carcinoma: immediate versus delayed findings at MR imaging. Radiology 2016; 278: 285-94. doi: 10.1148/radiol.2015150031
  103. Barabasch A, Distelmaier M, Heil P, Krämer NA, Kuhl CK, Bruners P. Magnetic resonance imaging findings after percutaneous irreversible electroporation of liver metastases: a systematic longitudinal study. Invest Radiol 2017; 52: 23. doi: 10.1097/RLI.0000000000000301
  104. Felker ER, Dregely I, Chung DJ, Sung K, Osuagwu FC, Lassman C, et al. Irreversible electroporation: defining the MRI appearance of the ablation zone with histopathologic correlation in a porcine liver model. AJR Am J Roentgenol 2017; 208: 1141-6. doi: 10.2214/AJR.16.17207
  105. Granata V, Fusco R, Salati S, Petrillo A, Bernardo ED, Grassi R, et al. A Systematic review about imaging and histopathological findings for detecting and evaluating electroporation based treatments response. Int J Environ Res Public Health 2021; 18: 5592. doi: 10.3390/ijerph18115592
  106. Cindrič H, Kos B, Tedesco G, Cadossi M, Gasbarrini A, Miklavčič D. Electrochemotherapy of spinal metastases using transpedicular approach - a numerical feasibility study. Technol Cancer Res Treat 2018; 17: 1533034618770253. doi: 10.1177/1533034618770253
  107. Pavliha D, Kos B, Marčan M, Zupanič A, Serša G, Miklavčič D. Planning of electroporation-based treatments using Web-based treatment-planning software. J Membr Biol 2013; 246: 833-42. doi: 10.1007/s00232-013-9567-2
  108. Marčan M, Pavliha D, Kos B, Forjanič T, Miklavčič D. Web-based tool for visualization of electric field distribution in deep-seated body structures and planning of electroporation-based treatments. Biomed Eng Online 2015; 14 (Suppl 3): S4. doi: 10.1186/1475-925X-14-S3-S4
  109. Perera-Bel E, Yagüe C, Mercadal B, Ceresa M, Beitel-White N, Davalos RV, et al. EView: an electric field visualization web platform for electroporationbased therapies. Comput Methods Programs Biomed 2020; 197: 105682. doi: 10.1016/j.cmpb.2020.105682
  110. Perera-Bel E, Aycock KN, Salameh ZS, Gómez-Barea M, Davalos RV, Ivorra A, et al. PIRET - a platform for treatment planning in electroporationbased therapies. IEEE Trans Biomed Eng 2022; 70: 1902-10. doi: 10.1109/TBME.2022.3232038.
  111. Paffi A, Apollonio F, Cadossi M, D’Alessio V, Fusco R, Giannini A, et al. A fast 3-D approach for electroporation treatment planning: optimal electrodes configuration. IEEE J Electromagn RF Microw Med Biol 2024; 8: 393-400. doi: 10.1109/JERM.2024.3409678
  112. Sertkaya A, DeVries R, Jessup A, Beleche T. Estimated cost of developing a therapeutic complex medical device in the US. JAMA Netw Open 2022; 5: e2231609. doi: 10.1001/jamanetworkopen.2022.31609
DOI: https://doi.org/10.2478/raon-2026-0040 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Language: English
Submitted on: Jun 17, 2026
Accepted on: Jul 13, 2026
Published on: Aug 12, 2026
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2026 Damijan Miklavcic, Helena Cindric, Rafael V Davalos, Frederic Deschamps, Julie Gehl, Bor Kos, Peter Kramar, Dimitrij Kuhelj, Martijn R Meijerink, Declan Soden, Miha Stabuc, Gregor Sersa, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.